2 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Recruiting 2 |
Follow Melissa Lumish: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 68Ga-PSMA-11 PET-directed Radioligand Therapy in Metastatic Hepatocellular Carcinoma (HCC) Lu-PSMA-617 - Liver Cancer, Hepatocellular Carcinoma | Phase 2 | Recruiting | Melissa Lumish | 10 | 2026-06-01 | 2026-05-08 |
| Oral TGF-beta Receptor I Inhibitor Vactosertib in SOC Chemoradiotherapy for Esophageal Adenocarcinoma Vactosertib, Standard of Care Preoperative Therapy - Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma | Phase 2 | Recruiting | Melissa Lumish | 25 | 2024-09-30 | 2026-10-05 |
Adenocarcinoma Of Esophagus (1) · Carcinoma, Hepatocellular (1) · Liver Neoplasms (1)
Carboplatin (1) · Folfox protocol (1) · Pluvicto (1) · vactosertib (1)
United States (2)